Recordati sizes up €10.9bn CVC Capital acquisition offer
Italian pharmaceutical company, Recordati, has confirmed that it’s weighing an acquisition offer from private equity manager, CVC, which is looking…
27 Mar 2026
J&J’s Darzalex nets first self-administered cancer injectable approval
Johnson & Johnson’s (J&J) blockbuster cancer immunotherapy, Darzalex (daratumumab), has secured European approval for self-administration, marking the first time an oncology injectable has achieved this milestone on the continent. Through…
27 Mar 2026
Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease
The US Food and Drug Administration (FDA) has approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel) in leukocyte adhesion deficiency type I (LAD-I), becoming the first pharmaceutical option for children with the…
27 Mar 2026
Novartis to acquire Excellergy for $2bn upfront
Novartis has signed an agreement to acquire biotech business Excellergy, which specialises in the development of next-generation anti-immunoglobulin e (IgE) therapies for up to $2bn in upfront and milestone payments. …
27 Mar 2026
Simulations Plus and three pharma companies collaborate on AI-driven drug development
Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled modelling in drug development. The partnerships aim to apply AI within scientifically validated modelling workflows and…
26 Mar 2026
Corcept’s first-in-class ovarian cancer drug gains FDA approval
Corcept Therapeutics has secured US approval for its selective glucocorticoid receptor agonist, Lifyorli (relacorilant), in ovarian cancer more than three months before its Prescription Drug User Fee Act (PDUFA) date…
26 Mar 2026
FDA opens door to feedback on ‘unclear’ national priority voucher pathway
The US Food and Drug Administration (FDA) will convene a public hearing intended to obtain feedback on its Commissioner's National Priority Voucher (CNPV) pilot programme, a framework that has garnered…